- Original research
- Open Access
The pharmacokinetics of [18F]UCB-H revisited in the healthy non-human primate brain
EJNMMI Research volume 11, Article number: 36 (2021)
Positron Emission Tomography (PET) imaging of the Synaptic Vesicle glycoprotein (SV) 2A is a new tool to quantify synaptic density. [18F]UCB-H was one of the first promising SV2A-ligands to be labelled and used in vivo in rodent and human, while limited information on its pharmacokinetic properties is available in the non-human primate. Here, we evaluate the reliability of the three most commonly used modelling approaches for [18F]UCB-H in the non-human cynomolgus primate, adding the coupled fit of the non-displaceable distribution volume (VND) as an alternative approach to improve unstable fit. The results are discussed in the light of the current state of SV2A PET ligands.
[18F]UCB-H pharmacokinetic data was optimally fitted with a two-compartment model (2TCM), although the model did not always converge (large total volume of distribution (VT) or large uncertainty of the estimate). 2TCM with coupled fit K1/k2 across brain regions stabilized the quantification, and confirmed a lower specific signal of [18F]UCB-H compared to the newest SV2A-ligands. However, the measures of VND and the influx parameter (K1) are similar to what has been reported for other SV2A ligands. These data were reinforced by displacement studies using [19F]UCB-H, demonstrating only 50% displacement of the total [18F]UCB-H signal at maximal occupancy of SV2A. As previously demonstrated in clinical studies, the graphical method of Logan provided a more robust estimate of VT with only a small bias compared to 2TCM.
Modeling issues with a 2TCM due to a slow component have previously been reported for other SV2A ligands with low specific binding, or after blocking of specific binding. As all SV2A ligands share chemical structural similarities, we hypothesize that this slow binding component is common for all SV2A ligands, but only hampers quantification when specific binding is low.
Synaptic vesicle glycoproteins (SV) are critical to proper nervous system function and have been demonstrated to be involved in vesicle trafficking. They belong to the Major Facilitator Superfamily (MFS) of transporters and consist of a 12-transmembrane glycoprotein and a cytoplasmic N-terminal region containing a long sequence that varies among the three SV2 isoforms (SV2A, SV2B and SV2C) [1, 2]. SV2A and -B are highly homologous to each other, with SV2A showing ubiquitous expression in both excitatory and inhibitory synapses throughout the entire brain [3, 4]; in contrast, SV2B and SV2C are present in a more restricted pattern in the brain, and in only a subset of synapses [2, 5]. The hypothesis of SV2 as vesicular transport protein is based on a significant homology to other transport proteins, however no endogenous substrate has been reported , neither has any transport activity been demonstrated . Another hypothetical function is vesicle trafficking and exocytosis, and the modification of the synaptic function [4,5,6].
Lynch and coworkers identified SV2A as the brain-binding site of the anti-epileptic drug levetiracetam (LEV, Keppra®, UCB Pharma Ltd., Slough, Berkshire, UK) . Seizure protection by LEV and other SV2A ligands strongly correlates with the degree of SV2A occupancy in vivo [3, 8]. However, the site of SV2A-LEV interaction and the mechanism of action remain unclear. LEV does not cause a SV2A conformational state change and it is assumed that SV2A transports LEV or LEV prevents transport of the endogenous substrate , as one of the functional consequences of LEV binding to SV2A in brain slices is reduced exocytosis . With the aim of a better understanding of the role of SV2A in epilepsy and of studying SV2A in diseases of the central nervous system, several SV2A-specific ligands have been developed , [18F]UCB-H being one of the first to be labelled , subsequently characterized in the rodent [10, 11], and in the human brain . The demonstration of the co-localization of SV2A with other synaptic markers using [11C]-UCB-J , showed the potential of in vivo imaging of the synaptic density using Positron Emission Tomography (PET), and led recently to the development of new [18F]-labelled ligands [9, 14,15,16,17,18,19]. Preclinical characterization of [18F]UCB-H has mostly been done in the rodent brain [20,21,22], while in non-human primates (NHP) limited data is available [23, 24]. In humans a preliminary study was performed on four healthy subjects , preceding a clinical study in Alzheimer’s patients . Here, we aimed to characterize pharmacodynamics properties of [18F]UCB-H in non-human cynomolgus primates in complement to these existing data and to discuss the obtained results in the light of the current state of SV2A PET ligands.
Material and methods
Experiments were conducted on four young adult male cynomolgus monkeys (Macaca fascicularis, 5.2 ± 1.1 kg, 4.4 ± 0.7 years). Animal use procedures were in accordance with the recommendations of the European regulations (EU Directive 2010/63) and approved by the local ethical committee (CETEA n°44), and the French Ministry of Education and Research (NEUROMODEL: APAFIS#389-20150327162135690v02). The experimental data reported in this study are in compliance with the ARRIVE (Animal Research: Reporting in Vivo Experiments) guidelines .
Radiosynthesis of the enantiomeric ligand [18F]UCB-H was realized through a one-step radiolabelling of a pyridyliodonium precursor as previously described . [18F]UCB-H was formulated in 0.9% aqueous saline with 3% ethanol (v/v). The radiochemical purity of [18F]UCB-H was > 98% and the molar activity at the time of injection was 54 ± 32 GBq/μmol.
All four non-human primates (NHP) underwent a 2-h (2 h) test and retest PET scan; two NHP underwent an additional 4-h (4 h) retest PET scan. Three NHP underwent one 4-h (4 h) displacement PET scan. Arterial blood sampling was performed during test and retest scans with PET imaging spaced by at least 3 weeks between each scan. To this end, the femoral artery opposite to the saphenous vein used for radioligand injection was cannulated. For the 2-h (2 h) scans, we collected in total 28 blood samples of 1 mL: 16 samples during the first 5 min followed by 3 samples every 5 min and 11 samples every 10 min. For the 4 h scans, we collected an additional 6 samples every 20 min during the last two hours (34 samples in total). Larger samples (2 – 3 mL) were collected at 5, 15, 30, 60, 90, 120 min (2 h) and at 180, 240 min (4 h) for metabolite analysis. Displacement of [18F]UCB-H was done by intravenous (IV) administration 90 min after [18F]UCB-H injection of a bolus of 30 mg/kg LEV, or of 80 µg/kg (≈250 nmol/kg) or 5 mg/kg (≈15 µmol/kg) of cold [19F]-UCB-H. Full experimental design of all NHP is outlined in Additional file 1: Table 1.
Solvents and LEV (C8H14N2O2; MM 170.21 g/mol) were obtained at Sigma-Aldrich® (France), and [19F]-UCB-H (C16H12F4N2O; MM 324.28 g/mol) was synthesised as previously described . Injectable solutions of [19F]-UCB-H for displacement studies were prepared with a mixture of Tetrahydrofuran (THF), Médialipide® and glucose at 2.5% as previously described . LEV was dissolved in a glucose solution of 2.5% to reach a concentration of 90 mg/mL.
PET imaging was performed on the microPET FOCUS220 (Siemens) under standard anesthesia and monitoring procedures . Data acquisition started with the IV bolus injection of [18F]UCB-H (32.9 ± 1.0 MBq/kg, 0.35 ± 0.07 µg/kg). Dynamic PET images were reconstructed using standard OSEM-2D algorithms while correcting for radioactive decay, scatter, attenuation and detectors inhomogeneity, which were measured prior to PET scanning using respectively 57Co and 68Ge external sources.
Blood measurement & analysis
Plasma was separated from whole-blood by centrifugation (5 min, 2054xg, 4 °C) and 50 µL of plasma and whole-blood were counted using a PET cross-calibrated gamma well counter (WIZARD2, PerkinElmer, France) to obtain the whole-blood and plasma activity curves. All data were corrected for radioactive decay from the injection time. For the larger blood samples, 500 µL plasma was deproteinized with acetonitrile. The supernatant was injected in high-performance liquid chromatography, equipped with an Atlantis® T3 5 μm 4.6 × 150 mm column (Waters) and an Atlantis® T3 5 μm 3.9 × 5 mm pre-column (Waters), with an LB-513 radioactivity flow detector (Berthold, La Garenne Colombes, France, MX Z100 cell). The eluant was collected in intervals of 15 s (fraction collector III, Waters, France) and counted in the gamma well counter (WIZARD2, PerkinElmer, France) to measure total activity. [18F]UCB-H parent fraction was calculated as a percentage of the total radioactivity (metabolites and parent).
For each animal, a 2-exponential decay function was fitted to [18F]UCB-H parent fraction, which was time multiplied with the plasma activity curve to obtain the metabolite-corrected arterial plasma input function (mcAIF) used for the kinetic modeling.
The fraction of [18F]UCB-H in NHP plasma samples not bound to plasma protein was measured before PET injection using a previously described ultrafiltration method . In brief, standard amounts of [18F]UCB-H (≈15 kBq) were added to 200 μL plasma that was applied to Microcon® filtration devices containing an YM-10 membrane (Millipore, France). The devices were centrifuged for 10 min at 10,000 g (Sigma 2-16KL, France). [18F]UCB-H activity concentration in the resulting ultrafiltrate (≈70 μL, CFP) and a sample of plasma (CP) were counted. The free fraction (fp) was calculated as: fp = CFP/CP and measured in triplicates.
PET data analysis
PET image analysis was performed using PMOD software version 3.8 (PMOD Technologies Ltd., Zurich, Suisse). After individual co-registration of PET-MR images, a cynomolgus atlas published by Ballanger and coworkers  was normalized to PET images to extract time activity curves in different brain regions. Volumes of interest (VOI) were cerebral white matter (16.7 cm3), striatum (0.24 cm3), thalamus (0.89 cm3), cerebellum (3.83 cm3), frontal—(2.50 cm3), parietal—(5.35 cm3), and temporal (8.22 cm3) cortex, and whole brain (72.2 cm3) as a composite region of all regions in the atlas. [18F]UCB-H pharmacokinetics were evaluated by analyzing the time activity curves of the test- and retest scans using 1- and 2-tissue compartment models (unconstrained and constrained with global K1/k2 coupled fit across all regions, further referred to as 2TCM and 2TCM-c) , and Logan graphical analysis with a fixed t* at 60 min  using the arterial plasma input function corrected for radio-metabolites to derive the volume of distribution in each region. Percentage standard error (%SE) was estimated from the theoretical parameter covariance matrix. Only reliable estimates (%SE less than 25%) were included in the current analyses. For the three drug studies, percent displacement of the total activity in the whole brain was estimated relative to an average baseline constructed from the two 4 h baseline studies. Briefly, Standardized Uptake Value (SUV) time activity curves (TACs) were calculated for the two baseline and the three displacement studies. Then, each curve was normalized to the SUV at t = 90 min, corresponding to the timeframe immediately before the administration of the drugs in the displacement studies. Baseline curves were averaged and the percent displacement of total activity was calculated as (baseline-displacement)/baseline at a given time post drug administration (see “Results”).
Statistical analysis was performed using R software (version 3.3.1.). Plasma, intact parent fraction and time activity curves were statistically compared between subjects using a one-factor variance analysis. Absolute Test–Retest variability (aTRV) of PET quantification parameters was calculated as ABS(test—retest) / AVERAGE(test, retest). Reliability was evaluated using a two-factor mixed model in order to calculate the intra-class correlation coefficient (ICC) (Package Psych, Version 1.7.8). All values are expressed as average ± standard error of the mean (SEM; significance level was fixed at p < 0.05).
[18F]UCB-H shows a rapid metabolism in the arterial blood with an intact parent fraction of 37 ± 3.9% at 15 min, 29.5 ± 3.4% at 30 min, 19 ± 3.5% at 60 min, 14.6 ± 1.9% at 120 min and 4.4 ± 0.7% at 240 min after tracer injection. The parent fraction was fitted with a two-exponential decay function based on blood data acquired up to 4 h after tracer injection, and on the residuals (Fig. 1a). Whole blood and plasma-input functions were highly consistent between animals with stable plasma to whole-blood ratio of 0.90 ± 0.05 over the entire 120-min acquisition period (Fig. 1b, c). Plasma free parent fraction (fp) measured by ultrafiltration before tracer injection was 42.6 ± 1.6%.
Time activity curves
Figure 2b shows representative time-activity curves (TACs) in a subset of brain regions. [18F]UCB-H entered rapidly in the brain, reaching maximal uptake 5 to 15 min after injection, followed by a relatively slow terminal elimination phase. Highest SUV uptake was observed in the striatum, followed by the thalamus and the cortical regions.
According to the lowest Akaike Information Criterion (AIC), the two-compartment model (2TCM) fitted better the TACs compared to the one-compartment model (1TCM) (AIC1TCM = 21.9 ± 1.8 vs. AIC2TCM = 0.71 ± 1.73). However, across all scans and VOI, VT estimated by 2TCM was only quantifiable (%SE < 25%) in 50% of cases (Fig. 3a and Additional file 1: Fig. 1). There was high uncertainty on the estimation of k3 and even higher for k4 where the estimate tended toward 0 in 30% of cases independent of the VOI, with therefore unreliable estimates of k3/k4 in > 80% of cases. 2TCM-c was more stable and enabled estimation of VT in 80% of cases, and of k3/k4 in 70% of cases. Logan graphical analysis fitted robustly all TACs, with a representative plot shown in Fig. 3b.
Figure 4a shows correlation plots between VT estimates obtained with Logan, 1TCM, 2TCM-c, and the cases for which 2TCM converged. Good agreement was found between 2TCM and Logan or 2TCM-c estimates (R2 = 0.90 and R2 = 0.91, respectively) with a slight overall underestimation of VT (-3 ± 1% for Logan, and -4 ± 1% for 2TCM-c), while 1TCM had a moderate correlation with 2TCM (R2 = 0.68) and overall larger bias for VT (-9 ± 1%) (Fig. 4b).
A summary of VT obtained by the different methods (2TCM, 2TCM-c, 1TCM and Logan) for different regions is shown in Table 1. aTRV and ICC were calculated for VT obtained by 2TCM-c, and Logan. Overall, aTRV were lower, and ICC were higher for Logan (~ 11% and ~ 0.6) compared to 2TCM-c (~ 17% and ~ 0.4) (Table 2).
As surrogate of BPND, k3/k4 obtained by 2TCM-c, was estimated to be 1.07 ± 0.02 on average; regional test, and retest values are detailed in Table 1. The tissue influx parameter of [18F]UCB-H (K1), a measure of blood flow and tracer extraction, was equal for 2TCM and 2TCM-c and estimated to 0.37 ± 0.01 mL/cm3/min in grey matter regions. The average VND (K1/k2 from 2TCM-c) over all VOIs and animals was 7.89 ± 1.23 mL/cm3, with a free fraction in tissue fND of 6.1 ± 1.3%. Additional file 1: Table 2 summarizes all individual estimates (< 25%SE) by 2TCM, 2TCM-c, 1TCM and Logan.
In all brain regions, [18F]UCB-H uptake was displaced by [19F]UCB-H in a dose-dependent manner with the displacement occurring rapidly; brain penetration of [19F]UCB-H is fast with maximum uptake 5–15 min after injection. Low dose of [19F]UCB-H (80 µg/kg, more than 100 fold [18F]UCB-H mass dose) resulted in ~ 20–25% displacement, and high dose of [19F]UCB-H (5 mg/kg) displaced close to 50% of [18F]UCB-H, where both measurements were estimated at 35 min after injection of cold [19F]UCB-H when the displacement was maximum (Fig. 3c).
LEV administration at pharmacological dose has a much slower brain penetration , and a dose of 30 mg/kg induced a slower displacement of [18F]UCB-H of ~ 40% as estimated at 150 min after injection of LEV (at the end of the 240 min acquisition) (Fig. 3c).
The current study evaluates [18F]UCB-H pharmacokinetics in healthy NHPs. We demonstrated similar metabolism in NHP as previously described in the rodent, human and rhesus monkey [11, 12, 23]. We have shown that [18F]UCB-H equilibrates rapidly between whole blood and plasma, with high availability in plasma (fp of 42.6 ± 1.6%). Similar to data obtained in rodent and human [11, 12], we observed in the NHP a good brain penetrance with ubiquitous brain uptake. Tissue influx parameters of [18F]UCB-H were comparable to other SV2A radioligands for grey matter regions [13, 24]. Even though a better goodness of fit of the TACs was obtained with 2TCM compared to 1TCM, not all TACs could be fitted with 2TCM. Previously, this has been the criteria to preconize the graphical method of Logan . Here we demonstrate that Logan provides reliable estimates of VT with a relatively low aTRV (~ 12%), although larger than that reported for [11C]UCB-J in humans (~ 4%), and a small bias relative to 2TCM of ~ -3% compared to ~ -9% for 1TCM. In a preliminary rhesus NHP study, Zheng and colleagues alternatively proposed 1TCM and the multilinear analysis method (MA1) to obtain reliable estimates of VT for [18F]UCB-H . Here, in the cynomolgus NHP, we demonstrated an aTRV above 10% for 1TCM and a poor reliability. For MA1 we found aTRV of VT (~ 11%), but a larger negative bias (~ -8%) compared to Logan (data not shown).
We observed that the convergence issue with 2TCM was mainly due to instability of the k4 estimate tending to zero in ~ 30% of all cases, independent of the regions. Brain kinetics of SV2A ligands [11C]UCB-J [35, 36] and [18F]SynVesT-1 (a.k.a [18F]SDM-8, [18F]MNI-1126)  have been reported as better described by 2TCM in human, but were better modeled with 1TCM in cynomolgus or rhesus monkeys [24, 37, 38], and [11C]UCB-A was better described with 1TCM at baseline in pigs but 2TCM was required after blocking of the specific signal . Interestingly, all authors reported issues with 2TCM similar to those reported here, namely lack of convergence or large standard error for VT [14, 35, 36, 39], with large uncertainty on k4 and values close to 0 [14, 35]. As a consequence, 1TCM for [11C]UCB-J and [18F]SynVesT-1 [14, 35], and Logan graphical analysis for [11C]UCB-A  was selected as method of choice. We reported here similar issues with the use of 2TCM for [18F]UCB-H. We obtained similar AIC for reversible or irreversible 2TCM, and spectral analysis indicated a component at the edge of the frequency range (data not shown), suggesting a small slow component for [18F]UCB-H. Although this component could reflect penetrating metabolites, inaccuracy of metabolite correction or vascularity activity correction, its exact nature remains unclear. Given the similarity in chemical structures between the current SV2A ligands and the aforementioned results reported in the literature, we hypothesize that this slow component is likely common between all these ligands. Moreover, this component is problematic when the specific signal is low (low affinity ligands or blocking studies) and when kinetics can only be described with 2TCM. This was nicely illustrated with [18F]MNI-1126 (high affinity of the (R)-enantiomer), [18F]MNI-1038 (racemate) and [18F]MNI-1128 (low affinity of the (S)-enantiomer) [24, 40], where 1TCM was the best model for [18F]MNI-1126, but 2TCM had to be used both for [18F]MNI-1038 and [18F]MNI-1128 (lower specific signal), with very low k4 for [18F]MNI-1128 . Here, similarly to [11C]UCB-A , the method of choice for [18F]UCB-H was Logan graphical analysis, as 1TCM was not adequate due to its lower affinity compared to other SV2A radioligands.
We performed homologous (with [19F]UCB-H) and heterologous (with reference compound LEV) displacement studies to evaluate the reversibility of [18F]UCB-H binding. The total uptake of [18F]UCB-H was clearly displaceable, and in a dose-dependent manner by [19F]UCB-H up to 50% of the total uptake at the highest dose tested (5 mg/kg). Based on [18F]UCB-H brain uptake curves and an fND of ~ 6%, we have a maximum free concentration of UCB-H of ~ 2.5 mM after administration 5.0 mg/kg. For UCB-H, in vitro Ki of 9 nM in human brain  and in vivo KD of 30 nM in NHP  were reported, and conservatively considering a KD of 30 nM, near full saturation of SV2A would be expected (> 98% occupancy) at a dose of 5 mg/kg and a free concentration of 2.5 mM. We have reported a maximum displacement of the total uptake of 50% with UCB-H, indicating that only about half of the total uptake is displaceable for [18F]UCB-H; therefore, BPND would be expected close to 1.0. Although imperfect because of all the microparameters correlations, k3/k4 from 2TCM with coupled fit K1/k2 was taken here as a surrogate of BPND to estimate the size of the specific signal and compare to previously reported results with other ligands. The expected BPND close to 1.0 is in agreement with the average value for k3/k4 of 1.1 reported in Table 1. Lower BPND values were reported in humans , however the binding potentials were derived relative to the centrum semiovale and would likely be higher if calculated using the true VND . Finally, the displacement study with LEV evidenced its slower brain penetrance compared to UCB-H, with a displacement of the total uptake of ~ 40% measured 2.5 h after 30 mg/kg i.v. LEV administration, which would correspond to an occupancy of ~ 75–80% of SV2A in agreement with values in the literature [14, 24, 38]. We observed some displacement in the white matter both with [19F]UCB-H and LEV. This is likely due to high spill-in from cortical regions rather than true specific signal in the white matter, as indicated by the higher than expected uptake and VT . Here, we coregistered T2-weighted MR-PET images to the Ballanger template  and used the inverse transformation to extract TACs from the PET images. Cynomolgus brains have relatively small white matter regions, with some inter-animal variability. Therefore, this approach appeared less precise to segment white matter regions, and prone to partial volume effect; as such, the current data set did not allow to use or evaluate the utility of the white matter as a reference region.
Altogether, our data confirm similar brain penetration and non-displaceable uptake for [18F]UCB-H as described for [11C]UCB-J , [18F]MNI1126  (aka [18F]Synvest-1 ). In agreement with previous reports in rhesus NHP [23, 38], VT-estimates and consequently BPND of [18F]UCB-H in cynomolgus NHP are considerably lower (~ 50% lower for VT, and 3 to fourfold lower for BPND) compared to VT and BPND measures with [11C]UCB-J [35, 38] and other [18F]-labelled SV2A radioligands, [18F]synvest1 [14, 16] and [18F]synvest2  (alias [18F]SDM-2 ). As a consequence, [18F]UCB-H will be less sensitive to detect small changes compared to the latest SV2A ligands. Nevertheless, a clinical study using [18F]UCB-H in Alzheimer’s Disease (AD) patients demonstrated a correlation between lower synaptic density and poorer awareness of memory functioning in Aβ-positive individuals , confirming earlier data in AD patients using [11C]UCB-J . Additionally, this [18F]UCB-H clinical study  suggested a widespread synaptic decline in AD patients across the neocortex and in some subcortical nuclei, including the basal forebrain, which was confirmed in a comparable but larger cohort of AD patients using [11C]UCB-J . These and other data  have demonstrated the potential of the [18F]UCB-H radioligand.
[18F]UCB-H was the first [18F]-labeled SV2A radioligand [10, 11], before a long series of new [18F]-labeled SV2A candidate ligands [17, 18, 24]. Here, we aimed to complete existing data on [18F]UCB-H by pharmacokinetic studies in young NHP. We show that, when specific binding is low, a slow component gives rise to compartment modeling difficulties with 2TCM due to instability of k4 estimation, which in 30% of all cases tends to 0. A similar observation has previously been reported for other SV2A candidate ligands [24, 39]. Graphical analysis allows nevertheless a reliable quantification of VT with acceptable aTRV and bias. Despite a lower sensitivity due to lower BPND, [18F]UCB-H recently provided sound data in a clinical AD study , paving the road for synaptic PET imaging using highly specific SV2A ligands in neurodegenerative disorders.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Percentage standard error
Akaike Information Criterion
Absolute Test–Retest variability
- BPND :
Non-Displaceable Binding Potential
- fp :
Plasma free parent fraction
Metabolite-corrected arterial plasma input function
Positron Emission Tomography
Standard error of the mean
Standardized uptake value
Volumes of interest
- VT :
Total Volume of Distribution
Synaptic vesicle glycoprotein 2A
Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994;14(9):5223–35.
Janz R, Sudhof TC. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience. 1999;94(4):1279–90.
Daniels V, Wood M, Leclercq K, Kaminski RM, Gillard M. Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays. Br J Pharmacol. 2013;169(5):1091–101.
Mendoza-Torreblanca JG, Vanoye-Carlo A, Phillips-Farfan BV, Carmona-Aparicio L, Gomez-Lira G. Synaptic vesicle protein 2A: basic facts and role in synaptic function. Eur J Neurosci. 2013;38(11):3529–39.
Bartholome O, Van den Ackerveken P, Sánchez Gil J, de la Brassinne BO, Leprince P, Franzen R, et al. Puzzling out synaptic vesicle 2 family members functions. Front Mol Neurosci. 2017;10:148.
Loscher W, Gillard M, Sands ZA, Kaminski RM, Klitgaard H. Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond. CNS Drugs. 2016;30(11):1055–77.
Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101(26):9861–6.
Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664(1–3):36–44.
Mercier J, Archen L, Bollu V, Carre S, Evrard Y, Jnoff E, et al. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands. ChemMedChem. 2014;9(4):693–8.
Bretin F, Warnock G, Bahri MA, Aerts J, Mestdagh N, Buchanan T, et al. Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H. EJNMMI Res. 2013;3(1):35.
Warnock GI, Aerts J, Bahri MA, Bretin F, Lemaire C, Giacomelli F, et al. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain. J Nucl Med. 2014;55(8):1336–41.
Bahri MA, Plenevaux A, Aerts J, Bastin C, Becker G, Mercier J, et al. Measuring brain synaptic vesicle protein 2A with positron emission tomography and [18 F]UCB-H. Alzheimer’s Dementia Transl Res Clin Intervent. 2017;3(4):481–6.
Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, et al. Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8(348):348–96.
Naganawa M, Li S, Nabulsi NB, Henry S, Zheng MQ, Pracitto R, et al. First-in-human evaluation of (18)F-SynVesT-1, a novel radioligand for PET imaging of synaptic vesicle protein 2A. J Nucl Med. 2020.
Mercier J, Provins L, Valade A. Discovery and development of SV2A PET tracers: potential for imaging synaptic density and clinical applications. Drug Discov Today Technol. 2017;25:45–52.
Constantinescu CC, Tresse C, Zheng M, Gouasmat A, Carroll VM, Mistico L, et al. Development and in vivo preclinical imaging of fluorine-18-labeled synaptic vesicle protein 2A (SV2A) PET tracers. Mol. Imaging Biol. 2018.
Cai Z, Li S, Zhang W, Pracitto R, Wu X, Baum E, et al. Synthesis and preclinical evaluation of an (18)F-labeled synaptic vesicle glycoprotein 2A PET imaging probe: [(18)F]SynVesT-2. ACS Chem Neurosci. 2020;11(4):592–603.
Cai Z, Li S, Finnema S, Lin S-f, Zhang W, Holden D, et al. Imaging synaptic density with novel 18F-labeled radioligands for synaptic vesicle protein-2A (SV2A): synthesis and evaluation in nonhuman primates. J Nucl Med. 2017;58(supplement 1):547.
Becker G, Dammicco S, Bahri MA, Salmon E. The rise of synaptic density PET imaging. Molecules (Basel, Switzerland). 2020;25(10).
Becker G, Warnier C, Serrano ME, Bahri MA, Mercier J, Lemaire C, et al. Pharmacokinetic characterization of [(18)F]UCB-H PET radiopharmaceutical in the rat brain. Mol Pharm. 2017;14(8):2719–25.
Serrano ME, Bahri MA, Becker G, Seret A, Mievis F, Giacomelli F, et al. Quantification of [(18)F]UCB-H binding in the rat brain: from kinetic modelling to standardised uptake value. Mol Imaging Biol. 2018.
Serrano ME, Becker G. Evaluating the in vivo specificity of [(18)F]UCB-H for the SV2A protein, compared with SV2B and SV2C in rats using micropet. 2019;24(9).
Zheng M-Q, Holden D, Nabulsi N, Lin S-f, Mercier J, Hannestad J, et al. Synthesis and evaluation of 18F-UCB-H, a novel PET imaging tracer for the synaptic vesicle protein 2A. J Nucl Med. 2014;55(supplement 1):1792.
Constantinescu CC, Tresse C, Zheng M, Gouasmat A, Carroll VM, Mistico L, et al. Development and in vivo preclinical imaging of fluorine-18-labeled synaptic vesicle protein 2A (SV2A) PET tracers. Mol Imaging Biol. 2019;21(3):509–18.
Bastin C, Bahri MA, Meyer F, Manard M, Delhaye E, Plenevaux A, et al. In vivo imaging of synaptic loss in Alzheimer’s disease with [18F]UCB-H positron emission tomography. Eur J Nucl Med Mol Imaging. 2020;47(2):390–402.
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage. 2012;20(4):256–60.
Warnier C, Lemaire C, Becker G, Zaragoza G, Giacomelli F, Aerts J, et al. Enabling efficient positron emission tomography (PET) imaging of synaptic vesicle glycoprotein 2A (SV2A) with a robust and one-step radiosynthesis of a highly potent (18)F-labeled ligand ([(18)F]UCB-H). J Med Chem. 2016;59(19):8955–66.
Goutal S, Langer O, Auvity S, Andrieux K, Coulon C, Caillé F, et al. Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates. Drug Deliv Transl Res. 2018;8(3):536–42.
Van Camp N, Balbastre Y, Herard AS, Lavisse S, Tauber C, Wimberley C, et al. Assessment of simplified methods for quantification of [(18)F]-DPA-714 using 3D whole-brain TSPO immunohistochemistry in a non-human primate. J Cerebral Blood Flow Metab. 2020;40(5):1103–16.
Tournier N, Cisternino S, Peyronneau MA, Goutal S, Dolle F, Scherrmann JM, et al. Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates. Pharm Res. 2012;29(9):2468–76.
Ballanger B, Tremblay L, Sgambato-Faure V, Beaudoin-Gobert M, Lavenne F, Le Bars D, et al. A multi-atlas based method for automated anatomical Macaca fascicularis brain MRI segmentation and PET kinetic extraction. Neuroimage. 2013;77:26–43.
Slifstein M, Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol. 2001;28(5):595–608.
Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10(5):740–7.
Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57(2):201–9.
Finnema SJ, Nabulsi NB, Mercier J, Lin SF, Chen MK, Matuskey D, et al. Kinetic evaluation and test-retest reproducibility of [(11)C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. J Cerebral Blood Flow Metab. 2017:271678x17724947.
Mansur A, Rabiner EA, Comley RA, Lewis Y, Middleton LT, Huiban M, et al. Characterization of 3 PET tracers for quantification of mitochondrial and synaptic function in healthy human brain: (18)F-BCPP-EF, (11)C-SA-4503, and (11)C-UCB-J. J Nucl Med. 2020;61(1):96–103.
Li S, Cai Z, Wu X, Holden D, Pracitto R, Kapinos M, et al. Synthesis and in vivo evaluation of a novel PET radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in nonhuman primates. ACS Chem Neurosci. 2019;10(3):1544–54.
Nabulsi NB, Mercier J, Holden D, Carré S, Najafzadeh S, Vandergeten M-C, et al. Synthesis and preclinical evaluation of 11C-UCB-J as a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the brain. J Nucl Med. 2016;57(5):777–84.
Estrada S, Lubberink M, Thibblin A, Sprycha M, Buchanan T, Mestdagh N, et al. [(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A. Nucl Med Biol. 2016;43(6):325–32.
Patel S, Knight A, Krause S, Teceno T, Tresse C, Li S, et al. Preclinical in vitro and in vivo characterization of synaptic vesicle 2A-targeting compounds amenable to F-18 labeling as potential PET radioligands for imaging of synapse integrity. Mol Imaging Biol. 2020;22(4):832–41.
Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, et al. Assessing synaptic density in alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol. 2018.
Mecca AP, Chen MK, O'Dell RS, Naganawa M, Toyonaga T, Godek TA, et al. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. Alzheimer's Dementia. 2020.
Serrano ME, Bahri MA, Becker G, Seret A, Germonpré C, Lemaire C, et al. Exploring with [(18)F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy. Mol Imaging Biol. 2020.
Authors are thankful to Leopold Eymin and Sophie Lecourtois for animal handling and PET acquisition. They also thank Romina Aron-Badin for animal care support and MRI acquisitions.
This work was supported by NeurATRIS: A translational Research Infrastructure for Biotherapies in Translational Neurosciences (Investissement d’Avenir – ANR-11-INBS-0011, A.L.P.)
Animal use procedures were in accordance with the recommendations of the European regulations (EU Directive 2010/63) and approved by the local ethical committee (CETEA n°44), and the French Ministry of Education and Research (NEUROMODEL: APAFIS#389-20150327162135690v02). The experimental data reported in this study are in compliance with the ARRIVE (Animal Research: Reporting in Vivo Experiments) guidelines .
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Goutal, S., Guillermier, M., Becker, G. et al. The pharmacokinetics of [18F]UCB-H revisited in the healthy non-human primate brain. EJNMMI Res 11, 36 (2021). https://doi.org/10.1186/s13550-021-00777-8
- Cynomolgus non-human Primates
- Synaptic imaging